JSM 2005 Online Program

Abstract #302474

This is the preliminary program for the 2005 Joint Statistical Meetings in Minneapolis, Minnesota. Currently included in this program is the "technical" program, schedule of invited, topic contributed, regular contributed and poster sessions; Continuing Education courses (August 7-10, 2005); and Committee and Business Meetings. This on-line program will be updated frequently to reflect the most current revisions.

To View the Program:
You may choose to view all activities of the program or just parts of it at any one time. All activities are arranged by date and time.

The views expressed here are those of the individual authors
and not necessarily those of the ASA or its board, officers, or staff.

The Program has labeled the meeting rooms with "letters" preceding the name of the room, designating in which facility the room is located:

Minneapolis Convention Center = “MCC” Hilton Minneapolis Hotel = “H” Hyatt Regency Minneapolis = “HY”

Back to main JSM 2005 Program page

Legend:

= Applied Session,

= Theme Session,

= Presenter

Activity Number:	243
Type:	Invited
Date/Time:	Tuesday, August 9, 2005 : 10:30 AM to 12:20 PM
Sponsor:	ENAR
Abstract - #302474
Title:	Statistical Issues Arising in the Women's Health Initiative
Author(s):	Ross Prentice*+
Companies:	Fred Hutchinson Cancer Research Center
Address:	1100 Fairview Ave N, POB 19024, M3-A410, Seattle, WA, 98109-1024,
Keywords:	genome-wide scan ; measurement error ; hazard ratio ; nutritional epidemiology ; observational study ; randomized controlled trial
Abstract:	A brief overview of the design of the Women's Health Initiative (WHI) Clinical Trial and Observational Study is provided in this paper, along with a summary of early results from the postmenopausal hormone therapy clinical trial components. Since its inception in 1992, the WHI has been faced with a number of statistical issues where further methodology developments are needed. These include measurement error modeling and analysis procedures for dietary assessment; clinical trial monitoring methods when treatments may affect multiple clinical outcomes, either beneficially or adversely; study design and analysis procedures for high-dimensional genomic and proteomic data; and failure time data analysis procedures when treatment group hazard ratios are time-dependent. This final topic seems important in resolving the discrepancy between WHI Clinical Trial results and observational studies of postmenopausal hormone therapy and cardiovascular disease.

The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.

Back to the full JSM 2005 program